Related Experiment Video
Updated: May 5, 2026
Intrastriatal Injection of Autologous Blood or Clostridial Collagenase as Murine Models of Intracerebral Hemorrhage
Published on: July 3, 2014
Efficacy and Safety of Atorvastatin for Chronic Subdural Hematoma: An Updated Systematic Review and Meta-Analysis
Gabriel de Almeida Monteiro1, Thomas Silva de Queiroz1, Ocílio Ribeiro Gonçalves2
1Department of Neurosurgery, Federal University of Ceara, Sobral, Brazil.
Insights
Atorvastatin significantly reduces chronic subdural hematoma recurrence, particularly with conservative treatment. This statin showed no increase in adverse effects, suggesting a potential role in CSDH management.
Area of Science:
- Neurology
- Pharmacology
Background:
- Chronic subdural hematoma (CSDH) is a prevalent neurological condition, disproportionately affecting the elderly population.
- Emerging research indicates atorvastatin may lower CSDH recurrence rates and enhance patient outcomes.
- Recent studies have expanded the evidence base since the last meta-analysis, incorporating larger sample sizes and diverse outcome measures.
Purpose of the Study:
- To conduct a meta-analysis evaluating the efficacy of atorvastatin in reducing CSDH recurrence.
- To assess the impact of atorvastatin on hematoma volume, adverse events, mortality, and neurological function.
- To synthesize current evidence on atorvastatin's role in managing CSDH.
Main Methods:
- A systematic literature search was performed across PubMed, Embase, and the Cochrane Central Register of Controlled Trials.
- Studies comparing atorvastatin use in CSDH patients against control or placebo groups were included.
- Primary outcome was CSDH recurrence; secondary outcomes included hematoma volume, adverse effects, mortality, and functional status (Glasgow Outcome Scale, Barthel index).
Main Results:
- Seven studies (1192 patients) revealed a significant reduction in overall CSDH recurrence with atorvastatin (RR 0.46; P=0.009).
- Subgroup analysis showed atorvastatin's benefit was significant in patients receiving conservative therapy (RR 0.40; P=0.001).
- No significant increase in adverse effects was observed (RR 0.82; P=0.44); however, atorvastatin did not show significant benefit when combined with surgery (RR 0.53; P=0.17).
Conclusions:
- Atorvastatin demonstrates potential in decreasing CSDH recurrence, especially when employed as part of conservative management strategies.
- The use of atorvastatin in CSDH patients was not associated with a significant increase in adverse effects.
- Further high-quality randomized controlled trials are warranted to definitively establish atorvastatin's efficacy, safety profile, and optimal dosage for CSDH treatment.
Background:
Chronic subdural hematoma (CSDH) is a common neurological condition, especially in the elderly population. Atorvastatin has shown the potential to reduce the recurrence of CSDH and improve overall outcomes. New studies have emerged since the last meta-analysis, increasing the sample size and the variety of outcomes analyzed.
Methods:
We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for studies comparing the use of atorvastatin in CSDH patients with a control group or placebo. The primary outcome was the recurrence of CSDH. Secondary outcomes of interest were hematoma volume, composite adverse effects, mortality, and neurological function, measured by the Glasgow Outcome Scale and Barthel index for activities of daily living.
Results:
Seven studies, of which 2 were randomized controlled trials, were included, containing 1192 patients. Overall recurrence significantly decreased compared to the control group (risk ratio [RR] 0.46; 95% confidence interval [CI] 0.25-0.83; P=0.009). The benefits of atorvastatin were sustained in the subgroup analysis of patients who underwent initial conservative therapy (RR 0.40; 95% CI 0.22-0.70; P=0.001). However, there was no significant difference when atorvastatin was combined with surgical intervention (RR 0.53; 95% CI 0.21-1.32; P=0.17). Adverse effects were not increased by atorvastatin (RR 0.82; 95% CI 0.51-1.34; P=0.44).
Conclusions:
Atorvastatin might be beneficial in reducing CSDH recurrence, especially in conservative treatment patients. Atorvastatin was not significantly associated with adverse effects. Larger, higher-quality randomized studies are needed to adequately evaluate the efficacy, safety, and optimal dose of atorvastatin in CSDH patients.
